Skip to main content

Zakrzewski Joseph S's Form 4 filing

Cyteir Therapeutics, Inc. (CYT) · filed Dec 15, 2021

Accession no.
0000899243-21-048432
Filed
Dec 15, 2021
Trade date
Dec 15, 2021
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $39.8K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Zakrzewski Joseph SCIK 0001331852Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2021Common StockPPurchaseAcquired+2,000$10.47F1+$20,94079,267Direct
Dec 15, 2021Common StockPPurchaseAcquired+1,700$11.12F3+$18,90480,967Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.95 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.95 to $11.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)